These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 15083288)

  • 1. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
    Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
    J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
    Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
    Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine.
    Taschner CA; Kirsch EC; Scheffler K; Wetzel SG; Schulte-Mönting J; Kappos L; Radü EW
    Magn Reson Imaging; 2005 Apr; 23(3):469-74. PubMed ID: 15862648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis.
    Swanton JK; Fernando KT; Dalton CM; Miszkiel KA; Altmann DR; Plant GT; Thompson AJ; Miller DH
    Mult Scler; 2010 Feb; 16(2):156-65. PubMed ID: 20086028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.
    Molyneux PD; Filippi M; Barkhof F; Gasperini C; Yousry TA; Truyen L; Lai HM; Rocca MA; Moseley IF; Miller DH
    Ann Neurol; 1998 Mar; 43(3):332-9. PubMed ID: 9506550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
    BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.
    De Stefano N; Giorgio A; Battaglini M; Rovaris M; Sormani MP; Barkhof F; Korteweg T; Enzinger C; Fazekas F; Calabrese M; Dinacci D; Tedeschi G; Gass A; Montalban X; Rovira A; Thompson A; Comi G; Miller DH; Filippi M
    Neurology; 2010 Jun; 74(23):1868-76. PubMed ID: 20530323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI.
    Rovaris M; Gallo A; Valsasina P; Benedetti B; Caputo D; Ghezzi A; Montanari E; Sormani MP; Bertolotto A; Mancardi G; Bergamaschi R; Martinelli V; Comi G; Filippi M
    Neuroimage; 2005 Feb; 24(4):1139-46. PubMed ID: 15670691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis.
    Parry A; Clare S; Jenkinson M; Smith S; Palace J; Matthews PM
    J Neurol; 2002 Sep; 249(9):1279-86. PubMed ID: 12242554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.
    Moraal B; van den Elskamp IJ; Knol DL; Uitdehaag BM; Geurts JJ; Vrenken H; Pouwels PJ; van Schijndel RA; Meier DS; Guttmann CR; Barkhof F
    Ann Neurol; 2010 May; 67(5):667-75. PubMed ID: 20437564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
    Smith ME; Stone LA; Albert PS; Frank JA; Martin R; Armstrong M; Maloni H; McFarlin DE; McFarland HF
    Ann Neurol; 1993 May; 33(5):480-9. PubMed ID: 8498825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis.
    Rovira A; Swanton J; Tintoré M; Huerga E; Barkhof F; Filippi M; Frederiksen JL; Langkilde A; Miszkiel K; Polman C; Rovaris M; Sastre-Garriga J; Miller D; Montalban X
    Arch Neurol; 2009 May; 66(5):587-92. PubMed ID: 19433658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.
    Bagnato F; Jeffries N; Richert ND; Stone RD; Ohayon JM; McFarland HF; Frank JA
    Brain; 2003 Aug; 126(Pt 8):1782-9. PubMed ID: 12821527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L; Parigi A; Barilaro A; Repice AM; Pellicanò G; Konze A; Siracusa G; Taiuti R; Amaducci L
    Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA.
    Neacsu V; Jasperse B; Korteweg T; Knol DL; Valsasina P; Filippi M; Barkhof F; Rovaris M; Vrenken H;
    J Magn Reson Imaging; 2008 Sep; 28(3):559-65. PubMed ID: 18777529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.